This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting the field of women’s reproductive health” and “India: Why is the country ramping up drug discovery research?”

Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. In the first article, Reece Armstrong speaks to Lisa Ricciardi, CEO of Cognition Therapeutics, to learn about what the company hopes to achieve with CT1812.

In the second article, DDW’s Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute’s (BII) Venture Lab acceleration programme, about the lack of innovation in women’s reproductive health and the company’s plans to fill the vacuum.

In the third article, I take a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest.